Diprosalic

How to order Diprosalic

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Diprosalic on Prescriptsy

Diprosalic is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Diprosalic is a combined topical preparation containing betamethasone dipropionate 0.05% (a potent corticosteroid) and salicylic acid 3% (a keratolytic agent).

It is licensed in the United Kingdom for the treatment of dry, scaly, hyperkeratotic dermatoses that are responsive to topical corticosteroid therapy, including psoriasis, chronic eczema with lichenification, ichthyosis, and seborrhoeic dermatitis of the scalp.

Diprosalic is available as an ointment for use on the body and as a scalp application (a liquid formulation designed for use through the hair).

It is manufactured by Organon (formerly MSD) and is a prescription-only medicine.

Psoriasis affects approximately 1.8% of the UK population, and a significant proportion of patients have plaque psoriasis characterised by raised, red patches covered with silvery-white scale.

Chronic eczema can also produce thickened, scaly, lichenified skin, particularly in areas subject to repeated scratching.

In both conditions, the accumulation of thick scale on the skin surface creates a physical barrier that reduces the penetration of standard topical treatments.

Diprosalic addresses this problem by combining a potent anti-inflammatory corticosteroid with a keratolytic agent that softens and removes the scale, thereby improving corticosteroid delivery to the inflamed skin beneath.

This page provides a comprehensive clinical overview of how Diprosalic works, correct use, expected timelines, side effects, safety warnings, and how to obtain a prescription in the UK.

Important safety information about Diprosalic

Before reading further, note the following essential safety points. Diprosalic is a prescription-only medicine (POM) in the UK and should be used under medical supervision.

• Diprosalic contains a potent corticosteroid. Use for the shortest duration and smallest area necessary. Do not exceed 4 weeks of continuous use on the body without medical review.
• Do not apply Diprosalic to the face, groin, or axillae unless a dermatologist specifically instructs this.
• Do not cover treated areas with airtight bandages or dressings unless directed by your doctor.
• Avoid applying to large areas of broken or inflamed skin due to the risk of salicylate absorption.
• Stop treatment and seek medical advice if the treated skin becomes thinner, develops stretch marks, or shows signs of infection.

Understanding psoriasis and hyperkeratotic skin conditions

Psoriasis is a chronic, immune-mediated inflammatory skin disease driven by overactivation of T-lymphocytes and excessive proliferation of keratinocytes in the epidermis.

Normal skin cell turnover takes approximately 28 days; in psoriatic plaques, this cycle is accelerated to 3 to 5 days.

The result is a build-up of immature skin cells on the surface, forming the characteristic thick, silvery scale.

Beneath the scale, the dermis is inflamed, with dilated capillaries producing the red appearance.

Chronic eczema (atopic dermatitis) can lead to lichenification, a thickening and hardening of the skin with accentuated skin markings, caused by repeated rubbing and scratching.

Like psoriatic scale, lichenified skin creates a barrier to topical treatments. Ichthyosis is a group of inherited or acquired conditions characterised by dry, scaly skin resembling fish scales.

Seborrhoeic dermatitis of the scalp produces erythema and greasy or dry scaling, particularly at the hairline and around the ears.

In all these conditions, the presence of excessive scale or thickened skin limits the effectiveness of standard topical corticosteroids applied alone.

By combining a keratolytic agent that removes this barrier with a potent anti-inflammatory corticosteroid, Diprosalic provides a rational approach to treatment.

How Diprosalic works: mechanism of action

Betamethasone dipropionate is a potent synthetic corticosteroid classified in Group III of the BNF potency ranking.

It exerts its therapeutic effect by crossing the cell membrane and binding to intracellular glucocorticoid receptors.

The activated receptor complex translocates to the cell nucleus and modulates gene transcription, upregulating the production of anti-inflammatory proteins (lipocortins) and downregulating pro-inflammatory mediators including interleukins, tumour necrosis factor alpha, prostaglandins, and leukotrienes.

The clinical effects are a reduction in redness, swelling, itching, and scaling.

Salicylic acid at 3% concentration acts as a keratolytic by disrupting intercellular adhesion (desmosomes) between corneocytes in the stratum corneum.

This softens and loosens the compacted layer of dead skin cells, allowing them to be shed more readily.

By removing the hyperkeratotic barrier overlying the inflamed dermis, salicylic acid enhances the penetration of betamethasone into the target tissue, improving its anti-inflammatory action.

Salicylic acid also has mild antiseptic properties.

The combination is synergistic: salicylic acid improves drug delivery while betamethasone controls the underlying inflammation and immune response. This dual mechanism makes Diprosalic more effective than either component alone for scaly, thickened dermatoses.

Clinical evidence and UK prescribing guidance

Betamethasone/salicylic acid combinations have been used in UK dermatology for several decades.

Clinical studies have demonstrated that the addition of salicylic acid to betamethasone dipropionate improves clinical outcomes in plaque psoriasis compared with betamethasone alone, particularly in plaques with significant scaling.

Scalp application formulations have shown high patient acceptability and efficacy in scalp psoriasis trials.

NICE Clinical Knowledge Summaries on psoriasis recommend potent topical corticosteroids as first-line treatment for trunk and limb plaque psoriasis, used for short courses (up to 4 weeks).

For the scalp, potent corticosteroid preparations are first-line, and keratolytic combinations such as Diprosalic scalp application are specifically recommended when scaling is prominent.

The BAD psoriasis guidelines similarly endorse combination corticosteroid/keratolytic preparations for hyperkeratotic plaques.

NICE guidance emphasises that topical corticosteroids should be used in a step-down approach: start with the potency needed to gain control, then step down to a milder preparation or emollient for maintenance.

Diprosalic is a treatment-phase preparation rather than a long-term maintenance product.

How to use Diprosalic correctly

Body (ointment)

Wash and dry the affected area gently. Apply a thin layer of Diprosalic ointment to the scaly, inflamed skin once or twice daily (once daily is usually sufficient).

Rub in gently until absorbed. Use the fingertip unit system to gauge the correct amount.

Do not apply to the face, groin, or axillae unless specifically directed by a dermatologist.

Scalp (scalp application)

Part the hair to expose the affected scalp. Apply the scalp application directly to the patches using the nozzle. Gently massage in.

The liquid formulation spreads easily through hair without the greasiness of an ointment. Apply once or twice daily as directed.

Duration and treatment cycles

Use Diprosalic for the shortest period needed to control the flare. On the body, this is generally no more than 2 to 4 weeks of continuous treatment.

Once scaling and inflammation are controlled, step down to an emollient, a milder corticosteroid, or a non-steroidal maintenance treatment such as a vitamin D analogue (calcipotriol).

For the scalp, slightly longer use may be appropriate, but regular review is needed.

Using with emollients

Emollients (unperfumed moisturisers) should be applied generously and frequently throughout treatment to maintain skin hydration and support the skin barrier.

Allow approximately 20 to 30 minutes between applying an emollient and Diprosalic to prevent dilution of the active ingredients or inadvertent spread to untreated areas.

Side effects of Diprosalic

Common side effects

The most common side effects are local and include burning, stinging, or itching at the application site, skin dryness, and folliculitis. These are generally mild and settle with continued use or reduction in application frequency.

Side effects from prolonged use

Prolonged or excessive use of potent topical corticosteroids is the primary source of adverse effects. Skin atrophy (thinning) manifests as fragile, translucent skin that bruises easily.

Striae (stretch marks) are irreversible once formed. Telangiectasia (visible small blood vessels) may develop. Perioral dermatitis and steroid rosacea can occur with facial use.

Hypertrichosis (increased hair growth) and hypopigmentation (skin lightening) at the application site are less common but documented effects.

With extensive or prolonged use, systemic absorption of betamethasone may lead to suppression of the hypothalamic-pituitary-adrenal (HPA) axis, Cushing-like features, and adrenal insufficiency.

This risk is increased in children, with use of occlusive dressings, and when applied to large body surface areas.

Salicylic acid applied to large areas of damaged skin may be absorbed systemically, potentially causing salicylism (tinnitus, nausea, vomiting, hyperventilation, metabolic acidosis).

This is rare at standard application areas but is a concern in children and in patients with renal impairment.

When to seek medical advice

Contact your GP or NHS 111 if you notice skin thinning, stretch marks, visible blood vessels, persistent irritation, or signs of skin infection (increasing redness, warmth, swelling, crusting, or pus).

If you experience dizziness, ringing in the ears, nausea, or rapid breathing while using Diprosalic on extensive areas, seek urgent medical attention as these may indicate salicylate toxicity.

Report adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Appropriate use and duration

Diprosalic is a potent corticosteroid combination and should not be used as a general moisturiser or applied to unaffected skin.

Follow the prescribed treatment duration and do not self-extend courses. If the condition relapses quickly after stopping, consult your prescriber rather than restarting without review.

Sensitive areas

The face, eyelids, groin, axillae, and other thin-skinned areas are at particular risk of corticosteroid side effects. Do not apply Diprosalic to these areas unless a specialist has specifically directed this. If Diprosalic contacts the eyes, rinse thoroughly with water.

Children

Children have a higher body surface area to weight ratio and are more susceptible to systemic corticosteroid absorption.

Use in children over 1 year should be limited to 5 to 7 days at a time, covering the smallest area necessary, and under medical supervision.

Diprosalic is not recommended for children under 1 year.

Infection

Topical corticosteroids suppress the local immune response and can mask the signs of skin infection. If a treated area becomes infected (increasing redness, warmth, swelling, crusting, or pus), start appropriate antimicrobial treatment and review the corticosteroid with your prescriber.

Pregnancy and breastfeeding

The safety of Diprosalic in pregnancy has not been fully established.

Potent topical corticosteroids should be used during pregnancy only if the benefit justifies the risk, in the smallest quantity for the shortest duration.

Avoid application to the breast during breastfeeding.

How to get a Diprosalic prescription in the UK

Diprosalic is a prescription-only medicine. Your GP can prescribe it following clinical assessment of your skin condition.

If you have moderate to severe or widespread psoriasis, your GP may refer you to an NHS dermatologist for a specialist treatment plan.

Authorised online prescribers registered with the General Pharmaceutical Council (GPhC) can also issue prescriptions following an appropriate clinical assessment.

The standard NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Managing psoriasis long term

Psoriasis is a long-term condition with a relapsing and remitting course. Diprosalic is designed for short-term flare management, not continuous daily use.

Between flares, maintain the skin with regular emollient use, consider maintenance topical therapy with vitamin D analogues (calcipotriol, calcitriol), and address known triggers including stress, infections, skin trauma, excessive alcohol, and smoking.

NICE recommends that patients with psoriasis have access to specialist review at least annually if disease is moderate to severe, and more frequently during active flares.

When to seek further medical advice

See your GP if your psoriasis or eczema is worsening despite treatment, if you notice skin thinning or stretch marks from topical corticosteroid use, or if you are uncertain about which treatments to use and when.

Seek urgent medical attention if you develop generalised pustular psoriasis (widespread pustules with fever and systemic illness) or erythroderma (redness covering most of the body surface), as these are medical emergencies.

Contact NHS 111 for advice on skin concerns outside GP hours.

Sources

• Diprosalic Ointment, Summary of Product Characteristics (EMC)
• Betamethasone with salicylic acid, British National Formulary (BNF)
• NICE CKS: Psoriasis
• Psoriasis, NHS
• British Association of Dermatologists, Psoriasis
• MHRA Yellow Card Scheme